In the present report, a method based on chip-based nanoelectrospray mass spectrometry (nanoESI-MS) is described to detect noncovalent ligand binding to the human estrogen receptor a ligand-binding domain (hERa LBD). This system represents an important environmental interest, because a wide variety of molecules, known as endocrine disruptors, can bind to the estrogen receptor (ER) and induce adverse health effects in wildlife and humans. Using proper experimental conditions, the nanoESI-MS approach allowed for the detection of specific ligand interactions with hERa LBD. The relative gasphase stability of selected hERa LBD-ligand complexes did not mirror the binding affinity in solution, a result that demonstrates the prominent role of hydrophobic contacts for stabilizing ER-ligand complexes in solution. The best approach to evaluate relative solution-binding affinity by nanoESI-MS was to perform competitive binding experiments with 17b-estradiol (E2) used as a reference ligand. Among the ligands tested, the relative binding affinity for hERa LBD measured by nanoESI-MS was 4-hydroxtamoxifen % diethylstilbestrol > E2 >> genistein >> bisphenol A, consistent with the order of the binding affinities in solution. The limited reproducibility of the bound to free protein ratio measured by nanoESI-MS for this system only allowed the binding constants (K d ) to be estimated (low nanomolar range for E2). The specificity of nanoESI-MS combined with its speed (1 min/ligand), low sample consumption (90 pmol protein/ligand), and its sensitivity for ligand (30 ng/mL) demonstrates that this technique is a promising method for screening suspected endocrine disrupting compounds and to qualitatively evaluate their binding affinity.Keywords: electrospray ionization mass spectrometry; noncovalent; nuclear receptor; estrogen receptor; endocrine disruptors; solution affinityThe estrogen receptor (ER) belongs to the nuclear receptor (NR) superfamily of ligand-activated transcription regulators, which are involved in many processes such as growth, organ differentiation, and development of reproductive tissues. The ER, which comprises a DNA-binding domain (DBD) and a ligand-binding domain (LBD), activates the transcription of target genes in response to the binding of estrogens, a group of steroid compounds, to the LBD. Once bound by hormones, the ER undergoes a conformational change that facilitates dimerization and subsequent interactions with the specific DNA sequence (Kumar and Chambon 1988;Steinmetz et al. 2001). The large hydrophobic cavity of the ER LBD allows the binding of a wide variety of nonsteroidal compounds through hydrophobic interactions. In the last decades, a variety of Reprint requests to: Renato Zenobi, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland; e-mail: zenobi@org.chem.ethz.ch; fax: 41 44 632 12 92.Article published online ahead of print. Article and publication date are at